Dorsal subthalamotomy for Parkinson's disease
- PMID: 11215596
- DOI: 10.1002/1531-8257(200101)16:1<72::aid-mds1019>3.0.co;2-6
Dorsal subthalamotomy for Parkinson's disease
Abstract
We report our experience of unilateral subthalamotomy in patients with Parkinson's disease (PD). Eleven patients were included in a pilot, open-labeled study to assess the effect of unilateral lesion of the subthalamic nucleus (STN) with a minimum of 12 months of follow-up. The guidelines of CAPIT (Core Assessment Program for Intracerebral Transplantation) were followed for recruitment into the study and follow-up assessment. Levodopa equivalents daily intake (mean 967 mg) were unchanged during the first 12 months in all but one patient who stopped medication. The sensorimotor region of the STN was defined by semimicrorecording and stimulation and a thermolytic lesion was placed accordingly. There was a significant reduction in both UPDRS parts II and III in the "off" state at 1-, 6-, and 12-month follow-up. This effect was maintained in four patients up to 24 months. The dyskinesia score did not change postoperatively. Lesion-induced dyskinesias were not a management problem except in one patient who developed a large infarction several days postsurgery. This initial study indicates that a lesion of the STN is not generally associated with hemiballismus in PD. Subthalamotomy may induce considerable motor benefit and could become another surgical option under specific circumstances.
Comment in
-
Subthalamotomy for end-stage severe Parkinson's disease.Mov Disord. 2002 May;17(3):625-7; author reply 627. doi: 10.1002/mds.10130. Mov Disord. 2002. PMID: 12112226 No abstract available.
Similar articles
-
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.Brain. 2005 Mar;128(Pt 3):570-83. doi: 10.1093/brain/awh397. Epub 2005 Feb 2. Brain. 2005. PMID: 15689366
-
Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.Br J Neurosurg. 2009 Feb;23(1):23-9. doi: 10.1080/02688690802507775. Br J Neurosurg. 2009. PMID: 19234905 Clinical Trial.
-
Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months.J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):979-85. doi: 10.1136/jnnp.2008.154948. Epub 2009 Feb 9. J Neurol Neurosurg Psychiatry. 2009. PMID: 19204026
-
The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma.Brain. 2001 Jan;124(Pt 1):5-19. doi: 10.1093/brain/124.1.5. Brain. 2001. PMID: 11133783 Review.
-
Subthalamotomy in the treatment of Parkinson's disease: clinical aspects and mechanisms of action.J Neurosurg. 2014 Jan;120(1):140-51. doi: 10.3171/2013.10.JNS13332. Epub 2013 Nov 8. J Neurosurg. 2014. PMID: 24205909 Review.
Cited by
-
Glutamate receptors and Parkinson's disease: opportunities for intervention.Drugs Aging. 2003;20(5):377-97. doi: 10.2165/00002512-200320050-00006. Drugs Aging. 2003. PMID: 12696997 Review.
-
Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review.Neuropsychol Rev. 2002 Jun;12(2):111-26. doi: 10.1023/a:1016806711705. Neuropsychol Rev. 2002. PMID: 12371602 Review.
-
Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments.J Pers Med. 2021 Jul 10;11(7):650. doi: 10.3390/jpm11070650. J Pers Med. 2021. PMID: 34357117 Free PMC article. Review.
-
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.Mov Disord. 2008 Apr 15;23(5):708-15. doi: 10.1002/mds.21906. Mov Disord. 2008. PMID: 18175345 Free PMC article.
-
Non-human primate models of PD to test novel therapies.J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8. J Neural Transm (Vienna). 2018. PMID: 28391443 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical